Filing Flows › Xilio Therapeutics (XLO) › Q1 2026 › vs Q1 2025
Xilio Therapeutics (XLO) Q1 2026 vs Q1 2025 (year over year)
Xilio Therapeutics's revenue rose $9.7M (+332%) from $2.9M in Q1 2025 to $12.6M in Q1 2026.
Xilio Therapeutics, Q1 2026: revenue $12.6M (+332% year over year), operating margin -111.6%, net loss $9.5M, operating cash flow −$22.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $12.6M | $2.9M | $9.7M | +332% |
| Other income, net | $4.6M | $586K | $4.0M | +682% |
| Net loss | $9.5M | $13.3M | −$3.7M | -28% |
| Costs & expenses | $26.8M | $16.8M | $10.0M | +59% |
| Operating costs | $26.8M | $16.8M | $10.0M | +59% |
| Research & development | $19.8M | $8.3M | $11.6M | +140% |
| General & admin | $6.9M | $8.5M | −$1.6M | -19% |
| Operating cash sources | $24.9M | −$26.9M | $51.8M | — |
| Depreciation & amortization | $344K | $497K | −$153K | -31% |
| Share-based compensation | $2.2M | $1.5M | $676K | +44% |
| Cash used in operations | $22.3M | −$29.0M | $51.3M | — |
| Net loss absorbed | $9.5M | $13.3M | −$3.7M | -28% |
| Working capital & other | $15.4M | −$40.2M | $55.6M | — |
Questions
How much did Xilio Therapeutics's revenue grow year over year in Q1 2026?
Xilio Therapeutics's revenue rose $9.7M (+332%) from $2.9M in Q1 2025 to $12.6M in Q1 2026.